XML 28 R20.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:

 

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

 

(In thousands)

 

Cash and cash equivalents

 

$

59,915

 

 

$

44,771

 

Restricted cash

 

 

1,846

 

 

 

1,846

 

Total cash, cash equivalents, and restricted cash

 

$

61,761

 

 

$

46,617

 

Summary of Segment Profit or Loss Including Significant Segment Expenses

The table below is a summary of the segment profit or loss, including significant segment expenses (in thousands):

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Collaboration revenue

 

$

3,320

 

 

$

7,874

 

 

$

4,366

 

 

$

11,548

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Compensation and benefits

 

 

7,067

 

 

 

14,262

 

 

 

15,315

 

 

 

30,819

 

Lab expenses and outside research services

 

 

4,809

 

 

 

2,903

 

 

 

8,256

 

 

 

6,127

 

Clinical supply costs

 

 

3,028

 

 

 

3,873

 

 

 

4,407

 

 

 

6,947

 

Clinical trials

 

 

1,371

 

 

 

7,081

 

 

 

4,755

 

 

 

14,094

 

Support functions

 

 

6,123

 

 

 

7,701

 

 

 

12,423

 

 

 

15,987

 

Other segment expenses(a)

 

 

5,315

 

 

 

6,192

 

 

 

8,522

 

 

 

16,407

 

Total operating expenses

 

 

27,713

 

 

 

42,012

 

 

 

53,678

 

 

 

90,381

 

Loss from operations

 

 

(24,393

)

 

 

(34,138

)

 

 

(49,312

)

 

 

(78,833

)

Other income, net

 

 

1,533

 

 

 

3,614

 

 

 

3,522

 

 

 

7,838

 

Income tax

 

 

130

 

 

 

 

 

 

130

 

 

 

 

Segment and consolidated loss

 

$

(22,990

)

 

$

(30,524

)

 

$

(45,920

)

 

$

(70,995

)

(a) Other segment expenses include consultants & contractor expense, contra-R&D expense for GSK collaboration, depreciation expense, impairment loss, restructuring expense, and stock-based compensation expense.